Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention.

Open Heart · 2019 · PMC6609142 · PMID 31328001

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep=0.06so close (0.05 < p ≤ 0.1)

Importantly, we have shown for the first time that patients receiving prasugrel had lower adjusted 30-day mortality compared with ticagrelor, a finding which approached, but did not reach statistical significance at 12 months (p=0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.